Ames, IA – According to filings with the U.S. Securities and Exchange Commission, Mazen Animal Health is raising $12,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jennifer Filbey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mazen Animal Health
Mazen Animal Health, Inc. is a biotechnology company transforming corn seed into the future of animal vaccines. We have produced proof of efficacy data in two vaccine candidates, each addressing a significant unmet need. By creating vaccines to be delivered orally with animal feed, Mazen provides elegant solutions to the challenges associated with injectable vaccines with:(1) increased production system ROI – removing the economic thresholds that control the vaccination decision today; (2) a safer method of vaccine administration for both animals and workers; (3) optimized vaccine efficacy allowing for reduced antibiotic use; and (4) vaccines with a global reach because of ambient temperature stability and ease of delivery. Mazens platform technology expresses antigens in corn seed and improves the standard vaccine manufacturing cost structure. These safe subunit antigen vaccines protect the animal by creating both mucosal and systemic immunity which should increase efficacy compared with current injectable vaccines. Corn seed containing antigen is ground into meal and added to animal feed. Cost effective disease prevention benefits the environment with decreased losses and increased productivity of protein to feed our planet.

To learn more about Mazen Animal Health, visit http://www.mazenanimalhealth.com/

Contact:
Jennifer Filbey, Chief Executive Officer
256-417-8568
jfilbey@mazenanimalhealth.com
https://www.linkedin.com/in/jennyfilbey/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved